STOCK TITAN
  1. Home
  2. News
  3. RDY

Dr Reddys Labs - RDY STOCK NEWS

Welcome to our dedicated page for Dr Reddys Labs news (Ticker: RDY), a resource for investors and traders seeking the latest updates and insights on Dr Reddys Labs stock.

Dr. Reddy's Laboratories Limited (RDY) is a leading multinational pharmaceutical company headquartered in Hyderabad, Telangana, India. Founded by Kallam Anji Reddy, the company has grown to become one of the largest generic drug manufacturers globally. Dr. Reddy's offers a diverse product portfolio that includes not only generic medications but also injectables and active pharmaceutical ingredients (APIs).

Dr. Reddy's has a substantial footprint in North America, which accounts for approximately 50% of its generics sales. The company also serves markets in India (22% of generics sales), Russia (12%), and various European and Latin American countries. In North America, injectables constitute 25% of its sales, showcasing the company’s ability to innovate and meet various healthcare needs.

Within branded generic markets, particularly in India, Dr. Reddy's has secured a top-five position in critical therapeutic areas such as oncology and gastroenterology. The company’s strong brand reputation has empowered it to achieve significant success in these sectors.

Furthermore, Dr. Reddy's operates a robust API business, manufacturing over 150 APIs and distributing them in more than 75 countries worldwide. This extensive network highlights the company's commitment to quality and global health.

Dr. Reddy's continues to advance its mission through ongoing projects and innovations. Recent achievements, partnerships, and financial health indicators demonstrate a stable and growing enterprise. Investors keen to stay informed about the latest developments in Dr. Reddy's Laboratories can find up-to-date news from various sources, ensuring they remain well-informed on company performance and growth trajectories.

News

Dr. Reddy's Announces the Acquisition of MenoLabs®, a Leading Women’s Health and Dietary Supplements Portfolio of Brands

Rhea-AI Summary
Dr. Reddy's Laboratories Ltd. (NYSE: RDY) has acquired MenoLabs® business, a leading women’s health and dietary supplement branded portfolio from Amyris, Inc. The acquisition includes seven branded products designed to provide health support and address symptoms of perimenopause and menopause, along with the MenoLife® health tracker app. This deal will accelerate Dr. Reddy's growth in the women’s nutritional and wellness markets, complementing their U.S. self-care and wellness business portfolio.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.45%
Tags
acquisition
-
News

Dr. Reddy’s becomes first Indian pharma company to debut on the Dow Jones Sustainability World Index

Rhea-AI Summary
Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) has achieved significant milestones in sustainability and Environment Social and Governance (ESG) initiatives. The company has secured 'Gold Medal' status from the global sustainability ratings agency, EcoVadis, and is featured in the Dow Jones Sustainability World Index for 2023, marking its debut in the index. Dr. Reddy's also retains its place in the Dow Jones Sustainability Emerging Markets Index for the 8th consecutive year. It has become the first Indian pharma company to pledge towards an integrated plantation initiative covering 2,900 hectares by 2028 as part of the World Economic Forum's 1t.org.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.91%
Tags
none
-
News

Coya Therapeutics, Inc. and Dr. Reddy’s Laboratories Enter into an Exclusive Collaboration for Development and Commercialization of COYA 302, an Investigational Combination Therapy for Treatment of Amyotrophic Lateral Sclerosis (ALS)

Rhea-AI Summary
Dr. Reddy's Laboratories SA (NYSE: RDY) and Coya Therapeutics, Inc. (NASDAQ: COYA) have entered into a development and license agreement for the commercialization of COYA 302, an investigational combination therapy for the treatment of Amyotrophic Lateral Sclerosis (ALS). The agreement grants Dr. Reddy's the exclusive rights to commercialize COYA 302 in the United States, Canada, the European Union, and the United Kingdom. The agreement includes an upfront payment of USD 7.5 million to Coya, with additional milestone payments of up to USD 40 million and sales-based milestone payments of up to USD 677.25 million. Dr. Reddy's will also pay royalties based on a percentage of net sales of COYA 302 ranging from low to middle teens. The development of COYA 302 was a result of a research collaboration between Coya and Houston Methodist in the laboratory of Dr. Stanley Appel.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.47%
Tags
none
News

Dr. Reddy’s Q2 FY24 Financial Results

Rhea-AI Summary
Dr. Reddy’s Laboratories Ltd. announces its consolidated financial results for Q3 2023. Revenues increased by 9% YoY and 2% QoQ. Gross margin is 58.7%. SG&A expenses increased by 13% YoY and 6% QoQ. R&D expenses are 7.9% of revenues. EBITDA is 31.7% of revenues. Profit before Tax increased by 19% YoY and 4% QoQ. Profit after Tax increased by 33% YoY and 6% QoQ.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.7%
Tags
earnings
-
News

Dr. Reddy's Laboratories Announces its Launch of Saxagliptin and Metformin Hydrochloride Extended-Release Tablets in the U.S.

Rhea-AI Summary
Dr. Reddy's Laboratories Ltd. (NYSE: RDY) announced the launch of Saxagliptin and Metformin Hydrochloride Extended-Release Tablets in the U.S. market, a generic version of KOMBIGLYZE® XR tablets. The tablets are approved by the USFDA and come in strengths of 2.5 mg/1000 mg and 5 mg/500 mg and 5 mg/1000 mg. The company also provided a link to the full prescribing information, including a boxed warning for LACTIC ACIDOSIS.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.32%
Tags
none
-
News

Dr. Reddy’s Q1 FY24 Financial Results

Rhea-AI Summary
Dr. Reddy’s Laboratories Ltd. announced its consolidated financial results for Q2 2023. Revenues increased by 29% YoY and 7% QoQ. Gross margin improved to 58.7%. Profit before tax increased by 26% YoY and 39% QoQ. Profit after tax increased by 18% YoY and 46% QoQ.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.25%
Tags
earnings
News

Dr. Reddy’s Proposed Rituximab Biosimilar Application Accepted for Review by USFDA, EMA and MHRA

Rhea-AI Summary
Dr. Reddy’s Laboratories announced that its Biologics License Application for its proposed biosimilar rituximab candidate DRL_RI has been accepted for review by the USFDA, EMA, and MHRA. The company expects to bring more biosimilar products to meet patient needs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.05%
Tags
none
-
News

Dr. Reddy’s Successfully Completes Phase I Study (IV Route) of DRL_TC, a Proposed Biosimilar of Tocilizumab

Rhea-AI Summary
Dr. Reddy's tocilizumab biosimilar candidate, DRL_TC, successfully met its primary and secondary endpoints in a Phase I study. The study demonstrated pharmacokinetic equivalence, safety, and immunogenicity compared to reference products. Dr. Reddy's is now initiating a global Phase III study to compare efficacy, safety, tolerability, and immunogenicity with the reference product.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.55%
Tags
clinical trial
-
News

Dr. Reddy’s Q4 & FY23 Financial Results

Rhea-AI Summary
Dr. Reddy’s Laboratories announced its financial results for Q4 and FY23. Q4 revenue was up 16% YoY and down 7% QoQ. Gross margin was 57.2%. EBITDA was 25.9% of revenues, up 26% YoY and down 17% QoQ. Profit before tax was up 434% YoY and down 19% QoQ. Profit after tax was up 996% YoY and down 23% QoQ.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.01%
Tags
earnings
News

Coya Therapeutics, Inc. Provides Business Update and Reports Q1 2023 Unaudited Financial Results

Rhea-AI Summary
Coya Therapeutics announces positive clinical data for COYA 302 in ALS patients and upcoming presentation on COYA 301 in Alzheimer's Disease. The company also appoints new Chief Business Officer and enters into licensing agreements.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.01%
Tags
earnings

FAQ

What is the current stock price of Dr Reddys Labs (RDY)?

The current stock price of Dr Reddys Labs (RDY) is $13.35 as of February 21, 2025.

What is the market cap of Dr Reddys Labs (RDY)?

The market cap of Dr Reddys Labs (RDY) is approximately 2.2B.

What does Dr. Reddy's Laboratories Limited specialize in?

Dr. Reddy's specializes in manufacturing generic medications, injectables, and active pharmaceutical ingredients (APIs).

Where is Dr. Reddy's Laboratories headquartered?

Dr. Reddy's Laboratories is headquartered in Hyderabad, Telangana, India.

Who founded Dr. Reddy's Laboratories?

Dr. Reddy's Laboratories was founded by Kallam Anji Reddy.

What percentage of Dr. Reddy's generics sales come from North America?

North America accounts for roughly 50% of Dr. Reddy's generics sales.

In which therapeutic areas has Dr. Reddy's established a strong presence in India?

Dr. Reddy's has a strong presence in oncology and gastroenterology in India.

How many active pharmaceutical ingredients (APIs) does Dr. Reddy's manufacture?

Dr. Reddy's manufactures over 150 APIs.

How many countries does Dr. Reddy's distribute its APIs to?

Dr. Reddy's distributes its APIs to more than 75 countries.

What significance do injectables have in Dr. Reddy's North America sales?

Injectables make up 25% of Dr. Reddy's North America sales.

What recent achievements has Dr. Reddy's Laboratories made?

Dr. Reddy's Laboratories has made significant recent achievements in product development and international partnerships.

How can investors stay updated on Dr. Reddy's latest developments?

Investors can stay updated on Dr. Reddy's latest developments by following news from credible sources and the company's announcements.
Stock RDY logo
Dr Reddys Labs

NYSE:RDY

RDY Rankings

#rank Ranked by Market Cap
#rank Ranked by Dividends

RDY Stock Data

2.24B
832.88M
14.25%
1.57%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
India
Hyderabad